Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 1 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07851636Not ApplicableNot Yet Recruiting

Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

NCT07087002Phase 1Recruiting

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Showing all 2 trials

Research Network

Activity Timeline